# Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

> clinical trial · VERIFIED · 2026-06-22

Status: ACTIVE_NOT_RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: Metastatic Angiosarcoma

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04668300

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.